印度已有一名新生儿参与一项具有里程碑意义的全球性临床试验，该试验有望改变医生治疗新生儿败血症这一婴儿主要杀手的方式。目前，用于治疗该疾病数十年的抗生素正迅速失效。

这项名为“全球新生儿败血症抗生素敏感性试验”（Global Neonatal Sepsis Antibiotic Susceptibility Trial，简称 GANSAT）的研究，旨在为全球范围内的新生儿败血症病例寻找更有效的治疗方案。由于耐药性细菌的出现，传统抗生素的效果正在减弱，这使得新生儿败血症的治疗面临严峻挑战。

参与该试验的印度新生儿，将接受一系列旨在评估新型治疗方法有效性和安全性的监测。研究人员希望通过收集来自不同地区的数据，能够更准确地了解哪些抗生素在对抗耐药菌株方面仍然有效，并探索新的治疗策略。

neonatal sepsis is a condition where bacteria enter the bloodstream of a newborn, causing a rapid, life-threatening response. It is responsible for an estimated 150,000 newborn deaths in India annually, and more than 200,000 globally. The World Health Organization (WHO) has declared antimicrobial resistance (AMR) a top global threat, and it is a particular concern in neonatal intensive care units (NICUs) in India, where infection rates are high.

The GANSAT trial, which began in Africa and is now expanding to Asia, involves 30 hospitals in India, including the All India Institute of Medical Sciences (AIIMS) in Delhi and the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh. It will recruit 1,000 newborns with sepsis, who will be randomly assigned to receive either standard treatment or a new treatment regimen. The trial is expected to last for three years.

“We are seeing increasing numbers of babies dying from sepsis in India because the antibiotics we have relied on for decades are no longer working,” said Dr. Rakesh Lodha, professor of pediatrics at AIIMS, who is leading the trial in India. “This trial is crucial because it will help us identify which antibiotics are still effective against the resistant bacteria that cause sepsis and inform new treatment guidelines.”

The rise of AMR is a complex problem driven by various factors, including the overuse and misuse of antibiotics in humans and animals, poor infection control in healthcare settings, and inadequate sanitation. In India, the problem is exacerbated by a high burden of infections and a large population, leading to increased antibiotic consumption.

“The situation is critical,” said Dr. Vineet Sehgal, head of neonatology at PGIMER. “We are running out of options. If we don’t find new solutions, we risk returning to a pre-antibiotic era where common infections could be fatal.”

The GANSAT trial is funded by the Bill & Melinda Gates Foundation and is being conducted in collaboration with the WHO and the Indian Council of Medical Research (ICMR). The results of the trial are expected to have a significant impact on the treatment of neonatal sepsis worldwide, potentially saving thousands of lives.

“This is a global challenge, and it requires a global solution,” said Dr. Soumya Swaminathan, Deputy Director-General of Programmes at the WHO. “The GANSAT trial is a vital step in the right direction, and we are hopeful that it will provide the evidence needed to combat this growing threat.”

The trial’s focus on newborns is particularly important, as they are highly vulnerable to infections and have underdeveloped immune systems. Neonatal sepsis can lead to severe complications, including brain damage, organ failure, and death, if not treated promptly and effectively.

The inclusion of India in the GANSAT trial is a significant development, given the country’s high burden of neonatal sepsis and its role as a major hub for medical research. The insights gained from this trial could pave the way for new antibiotic stewardship programs and improved infection control measures, not only in India but also in other countries facing similar challenges.

The trial’s success will depend on the active participation of healthcare professionals, researchers, and patients, as well as continued global cooperation and investment in combating AMR. The fight against drug-resistant sepsis is a race against time, and the GANSAT trial represents a crucial effort to win that race for the world’s newborns.

这项名为“全球新生儿败血症抗生素敏感性试验”（GANSAT）的研究，旨在为全球新生儿败血症患者寻找更有效的治疗方案。新生儿败血症是指细菌进入新生儿血流，引发快速且危及生命的反应，据估计每年导致印度约15万名新生儿死亡，全球则超过20万。世界卫生组织（WHO）已将抗菌素耐药性（AMR）列为全球首要威胁，在印度的新生儿重症监护室（NICUs）中，由于感染率高，这一问题尤为突出。

GANSAT试验已在非洲启动，并扩展至亚洲，包括印度德里的全印度医学科学研究所（AIIMS）和昌迪加尔的医学教育与研究研究生院（PGIMER）在内的30家医院。该试验将招募1000名患有败血症的新生儿，他们将被随机分配接受标准治疗或新的治疗方案。预计试验将持续三年。

AIIMS儿科教授、印度试验负责人Rakesh Lodha医生表示：“我们看到越来越多的婴儿因败血症在印度死亡，因为我们数十年来依赖的抗生素已不再有效。这项试验至关重要，因为它将帮助我们确定哪些抗生素对引起败血症的耐药菌仍然有效，并为新的治疗指南提供依据。”

抗菌素耐药性的上升是一个复杂问题，由多种因素驱动，包括人类和动物抗生素的过度使用和滥用、医疗机构感染控制不力以及卫生设施不足。在印度，感染负担沉重和人口众多加剧了这一问题，导致抗生素消耗量增加。

PGIMER新生儿科主任Vineet Sehgal医生说：“情况非常危急，我们的选择越来越少。如果我们找不到新的解决方案，就有可能回到抗生素出现之前的时代，那时常见的感染就可能致命。”

GANSAT试验由比尔及梅琳达·盖茨基金会资助，并与世界卫生组织及印度医学研究理事会（ICMR）合作进行。试验结果预计将对全球新生儿败血症的治疗产生重大影响，可能挽救数千人的生命。

世界卫生组织（WHO）项目副总干事Soumya Swaminathan医生表示：“这是一个全球性挑战，需要全球性的解决方案。GANSAT试验是朝着正确方向迈出的重要一步，我们希望它能提供对抗这一日益增长威胁所需的证据。”

该试验特别关注新生儿，因为他们极易受到感染，且免疫系统尚未发育成熟。如果不能及时有效地治疗，新生儿败血症可能导致严重的并发症，包括脑损伤、器官衰竭和死亡。

考虑到印度新生儿败血症的高发率以及其作为主要医学研究中心的地位，印度参与GANSAT试验具有重要意义。该试验获得的见解可能为新的抗生素管理计划和改进的感染控制措施铺平道路，不仅在印度，也在其他面临类似挑战的国家。

试验的成功将取决于医疗专业人员、研究人员和患者的积极参与，以及持续的全球合作和对抗菌素耐药性斗争的投资。与耐药性败血症的斗争是一场与时间的赛跑，而GANSAT试验代表着赢得这场为全球新生儿而战的关键努力。